ProKidney
PROK
67 hedge funds and large institutions have $187M invested in ProKidney in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 23 closing their positions.
16% less funds holding
Funds holding: 80 → 67 (-13)
16.54% less ownership
Funds ownership: 91.45% → 74.91% (-17%)
19% less capital invested
Capital invested by funds: $232M → $187M (-$45.1M)
57% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 23
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$7.42M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$5.42M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$3.58M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.03M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$10.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.1M |
| 3 |
TCA
Taconic Capital Advisors
New York
|
-$4.94M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$4.46M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$4.3M |
PROK Hedge Fund Activity: Q2 2022 in Review
67 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ProKidney (PROK) for Q2 2022, worth a combined $187M — down 19% from $232M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PROK and 10 opened new positions — a net loss of 13 holders — while 17 trimmed existing stakes and 7 added.
The largest buyer was First Trust Capital Management, adding an estimated $7.42M. The largest seller was Kepos Capital, exiting entirely with an estimated $10.9M sold.
- 67 institutional investors held ProKidney (PROK) as of Q2 2022, down from 80 in Q1 2022.
- Funds reported $187M of ProKidney stock for Q2 2022, down 19% quarter-over-quarter.
- 10 funds opened new ProKidney positions in Q2 2022 and 23 closed out, a net change of -13 holders.
- The largest ProKidney buyer in Q2 2022 was First Trust Capital Management, an estimated $7.42M added.
- The largest ProKidney seller in Q2 2022 was Kepos Capital, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2022.